News

FDA halts sale of off-brand Ozempic and other GLP-1 drugs
A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...
Fierce Biotech5h
Chutes & Ladders—Weight of market pressures pushes Novo CEO out
Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—is heading for the exit.
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
NVO CEO Resigns Amid Ongoing Challenges
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
STAT5h
New budget bans Medicaid coverage of trans gender-affirming care
How a new Trump plan could make science ‘a political football’ The NIH is already in turmoil. Billlions of dol ...